Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CPT2 | P23786 | 3/20 | 0.34 |
| ▸ | CPT1A | P50416 | 3/20 | 0.34 |
| ▸ | CPT1B | Q92523 | 3/20 | 0.34 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3754257 | 0.88 | HTR6 (0.68) | HTR6EPHX2AVPR1B | |
| SCHEMBL3751473 | 0.82 | HTR6 (0.82) | HTR6 | |
| SCHEMBL3746678 | 0.71 | HTR6 (1.00) | HTR6AVPR1B | |
| SCHEMBL3750919 | 0.70 | HTR6 (0.67) | HTR6MEN1KMT2AALDH1A1AVPR1B | |
| SCHEMBL3757147 | 0.67 | PDE4A (0.55) | HTR6LMNA | |
| SCHEMBL14606805 | 0.65 | HTR6 (0.49) | HTR6MEN1KMT2AALDH1A1POLB | |
| SCHEMBL13947280 | 0.64 | HTR6 (0.58) | HTR6ALDH1A1POLBCYP3A4CYP2C9 | |
| SCHEMBL12827783 | 0.64 | MAPT (0.42) | HTR6MEN1KMT2AALDH1A1POLB | |
| SCHEMBL3744515 | 0.64 | HTR6 (0.74) | HTR6ALDH1A1AVPR1B | |
| SCHEMBL13368608 | 0.64 | HTR6 (0.70) | HTR6MEN1KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838518-B2 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | N.V. ORGANON (NL) | 2010-11-23 | — | — | US | disclosed |
| EP-1476151-B1 | 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ORGANON NV (NL) | 2008-07-16 | — | — | EP | disclosed |
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | MERCK SHARP & DOHME B.V. (NL) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | TPH1, HTR1A, HTR1D | HTR6 12/4885EPHX2 4625/4885MEN1 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.